FDA Approves Cabenuva, the First Complete Long-Acting Injectable HIV Treatment

FDA Approves Cabenuva, the First Complete Long-Acting Injectable HIV Treatment

On January 21, the Food and Drug Administration (FDA) approved the first complete injectable HIV treatment regimen that does not require daily pills. They were randomly assigned to either stay on their current oral regimen or switch to Cabenuva injections after an oral lead-in. Reasons included greater convenience, having to think about HIV treatment only 12 times a year and not having pill bottles that could reveal their HIV status to others. Once-monthly Cabenuva for HIV treatment was first approved in Canada in March 2020. “Cabenuva once-monthly injections showed comparable efficacy to daily oral antiretroviral treatment in maintaining viral suppression—a first in the treatment paradigm.”Click here for full prescribing information for Cabenuva.

About Us

At Wellness Axis we want to encourage habits of wellness, Increase awareness of factors and resources contributing to well-being, Inspire and empower individuals to take responsibility for their own health, and to support a sense of community. Wellness can be thought of as the quality or state of being in good health.

Subscribe to our newsletter!